The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

The FDA has approved Medtronic plc's (NYSE: MDT) InterStim X, the next generation of the InterStim portfolio's recharge-free device. InterStim systems deliver sacral neuromodulation (SNM) therapy ...

DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim (TM) smart programmer for use with the InterStim system, which ...

Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...

Axonics is still neck-and-neck with Medtronic in the sacral neuromodulation space. The company anticipates receiving the FDA’s approval for its own recharge-free implant later this year.

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals ...

Like the InterStim X, Axonics’ F15 implant is designed to deliver electrical stimulation directly to the sacral nerve, blocking the neurological signals linked to bladder and bowel dysfunction.

Medtronic has treated more than 300,000 patients with recharge-free InterStim systems and, now, the rechargeable InterStim Micro and SureScan leads for the InterStim Micro and InterStim II systems ...

Medtronic’s MDT neuromodulation business advanced recently with the company receiving FDA’s expanded MRI labeling approval for its InterStim line of sacral neuromodulation (SNM) systems.